Document is current
Any future updates will be listed below
-
Authors
Anderson, Nathaniel D.
Birch, Jack
Accogli, Theo https://orcid.org/0000-0002-2783-8482
Criado, Ignacio https://orcid.org/0000-0003-4120-343X
Khabirova, Eleonora
Parks, Conor https://orcid.org/0000-0003-0240-0684
Wood, Yvette
Young, Matthew D. https://orcid.org/0000-0003-0937-5290
Porter, Tarryn https://orcid.org/0000-0002-6063-0659
Richardson, Rachel
Albon, Sarah J.
Popova, Bilyana
Lopes, Andre
Wynn, Robert https://orcid.org/0000-0002-6046-8428
Hough, Rachael
Gohil, Satyen H.
Pule, Martin
Amrolia, Persis J. https://orcid.org/0000-0003-0480-3911
Behjati, Sam https://orcid.org/0000-0002-6600-7665
Ghorashian, Sara https://orcid.org/0000-0002-1555-2946
- License Information
-
More Information
Article History
Received: 22 December 2022
Accepted: 23 May 2023
First Online: 6 July 2023
Competing interests
: M.A.P. is employed by and owns stock in Autolus, Ltd., which has licensed the CD19 CAR. S.G., M.A.P. and P.J.A. have patent rights for CAT CAR in targeting CD19 and may receive royalties from Autolus Therapeutics PLC (patent application: World Intellectual Property Organization, WO 2016/139487 Al). N.D.A., S.B. and S.G. have filed a patent application related to the use of a transcriptional signature to determine a persistence phenotype in CAR-T cells. The remaining authors declare no competing financial interests.
